Company: LCTX
Filing Date: 2025-03-10
Form Type: 10-K
Source: 0000950170-25-036309
Chunk: 259

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-03-10
Form: 10-K
Item: Item 8
Chunk 259
---
,672

    Intangible assets, net

    46,540

    46,562

    TOTAL ASSETS
     
    $
    113,218

    $
    101,019

    LIABILITIES AND SHAREHOLDERS’ EQUITY

    CURRENT LIABILITIES

    Accounts payable and accrued liabilities
     
    $
    5,437

    $
    6,270

    Operating lease liabilities, current portion

    1,097

    830

    Finance lease liabilities, current portion

    55

    52

    Deferred revenues, current portion

    7,388

    10,808

    Total current liabilities

    13,977

    17,960

    LONG-TERM LIABILITIES

    Deferred tax liability

    273

    273

    Deferred revenues, net of current portion

    14,433

    18,693

    Operating lease liabilities, net of current portion

    1,295

    1,979

    Finance lease liabilities, net of current portion

    67

    91

    Warrant liabilities

    6,161

    —

    TOTAL LIABILITIES

    36,206

    38,996

    Commitments and contingencies (Note 13)

    SHAREHOLDERS’ EQUITY

    Preferred shares, no par value, 2,000 shares authorized; none issued and    outstanding as of December 31, 2024 and 2023

    —

    —

    Common shares, no par value, 450,000 shares authorized as of    December 31, 2024 and 2023; 220,416 and 174,987 shares issued    and outstanding as of December 31, 2024 and 2023, respectively

    484,722

    451,343

    Accumulated other comprehensive loss

    (2,876
    )

    (3,068
    )

    Accumulated deficit

    (403,465
    )

    (384,856
    )

    Lineage's shareholders’ equity

    78,381

    63,419

    Noncontrolling deficit

    (1,369
    )

    (1,396
    )

    Total shareholders’ equity

    77